New therapies – Niemann-Pick type C disease
on Nov 21 in Blog, News, Therapies, What is NPC posted Jackie Imrie, James E Wraith, Manchester, Miglustat, Niemann-Pick Type C Disease, NP-C, NPC, Research, Royal Manchester Children’s Hospital, Therapies, UK, Willink Biochemical Genetics Unit, Zevesca by Michael G Stults
New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat
Authors: James E Wraith, Jackie Imrie
Published Date November 2009
James E Wraith, Jackie Imrie
Willink Biochemical Genetics Unit, Royal Manchester Children’s Hospital, Manchester, UK
Abstract: Niemann-Pick disease type C (NP-C) is an autosomal recessive disorder characterized by progressive neurological deterioration leading to premature death. The disease is caused by mutations in one of two genes, NPC1 or NPC2, leading to impaired intracellular lipid transport and build-up of lipids in various tissues, particularly the brain.
*This post does not reflect the views and opinions of Niemann-Pick Children’s Fund, Inc. This article is for informational purposes only. The sole credit of this article belongs to the author/website listed above.
No Comments Leave a comment
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment